Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure. The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-c-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG 3À7 ), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS). Using DNaseI assays, we identified a hypersensitive site upstream from exon-1, suggesting chromatin remodeling could alter FPGS expression. We demonstrated that histone deacetylase-1 (HDAC1) is recruited by NFY and Sp1 transcription factors to the FPGS promoter in ALL cell lines. We examined the effect of histone deacetylase inhibitors (HDACIs) sodium butyrate and suberoylanilide hydroxamic acid (SAHA) on the expression of FPGS and other folate-related genes. HDACIs increased FPGS mRNA expression by 2-to 5-fold, whereas DHFR and TS mRNA expression was decreased. Combination treatment with MTX plus SAHA significantly increased cytotoxicity and apoptosis in B-and T-ALL cell lines as compared with each drug alone (CIp0.8). SAHA increased the intracellular accumulation of long-chain MTX-PG 3À7 . Therefore, HDACI-induced FPGS expression increases the accumulation of MTX-PG 3À7 and cytotoxicity in ALL cell lines, which is potentiated by DHFR and TS downregulation. The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.
Introduction
Childhood acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children and adolescents. 1 Despite significant advances in cure rates (event-free survival B80%), outcome remains poor for patients who present with resistant phenotypes (Bcr/Abl-positive; MLL-rearranged ALL, induction failures, etc) or for those who suffer a relapse (event-free survival o20%). 1 In this context, ALL continues to be the number one cause of cancer-related deaths among patients under the age of 19 years. 1 Therefore, novel combination treatment strategies are needed to further improve cure rates and decrease overall mortality.
Folate cofactors are essential components of one-carbon metabolism and are required for biosynthesis of purines, pyrimidine, serine and methionine. 2 The classical folate antagonist methotrexate (MTX) continues to be a universal component and cornerstone of most ALL multi-modality treatment regimens. 3 In mammalian tissues, reduced folates and classical antifolates like MTX exist as intracellular poly-g-glutamates, with typical chains ranging from five to nine residues. [4] [5] [6] Polyglutamation is catalyzed by the enzyme folylpoly-g-glutamate synthetase (FPGS). 7 When polyglutamated, some antifolates (for example, pemetrexed, raltitrexed) increase their K i against targeted enzymes by over 100-fold. 8, 9 For MTX, the net pharmacological effect of polyglutamation (MTX polyglutamate (MTX-PG)) is prolonged intracellular retention and increased dihydrofolate reductase (DHFR) inhibition, 7 plus inhibition of additional key folate-related enzymes such as thymidylate synthase (TS) and aminoimidazolecarboxamide ribonucleotide formyl transferase (reviewed by Fotoohi and Albertioni 7 ). These latter two enzymes are not inhibited by the parent MTX monoglutamated drug. In childhood ALL a strong correlation exists between FPGS expression, intracellular MTX-PG accumulation and treatment outcome. [10] [11] [12] [13] Our laboratory and others have demonstrated using real-time quantitative reverse transcription-PCR (qRT-PCR), enzymatic activity assays and gene microarrays that FPGS expression (mRNA and enzyme activity) is lineage-specific, with higher level in B-precursor (Bp)-ALL when compared with that in T-lineage (T)-ALL, in both cell line models and clinical samples from patients with ALL. 10, 14, 15 In normal and malignant lymphohematopoietic cells, the FPGS gene is controlled by at least two mechanisms: one tissue-specific (lineage-specific) and a second proliferation-dependent. 10, 16 FPGS activity is distributed to both cytosolic and mitochondrial compartments of mammalian cells. In humans, these two isoforms are encoded by a single locus in chromosome region 9q (34.1-34.2) , and differ by the use of two alternative translational start sites within exon-1. 17, 18 Transcription of the human FPGS gene is controlled by a TATA-less promoter driven by a set of eight concatameric Sp1 sites spaced within a 150-bp region upstream from exon-1. 18 We recently showed that the NFY (Y-box) transcription factor also plays an important role in the control of FPGS transcription. 19 Epigenetic modifications such as nucleosomal histone acetylation by histone acetyltransferases (HATs) and deacetylation by histone deacetylases (HDACs) are important modulators of gene expression and act by altering chromatin structure and function. 20, 21 Histone deacetylase inhibitors (HDACIs), a novel class of anticancer agents, inhibit the deacetylation of histones and relax chromatin scaffolding, altering gene transcription. 22 As a result, HDACIs are able to activate differentiation, arrest cell-cycle progression in G 1 and/or G 2 , and induce apoptosis in transformed cancer cells. 22 In the present study, we investigated the effects of HDACIs on the expression of folate-related enzymes and MTX metabolism in ALL cell lines. Our results show that FPGS gene expression is increased by treatment of ALL cell lines with pan-HDACIs such as sodium butyrate (NaBu) and suberoylanilide hydroxamic acid (SAHA). We demonstrate that modulation of FPGS expression by HDACI likely results from Sp1 recruitment of HDAC1 to form a complex in the presence of NFY, which leads to enhanced FPGS expression. On this basis, we then examined the effects of HDAC inhibition by NaBu and SAHA on MTX metabolism and cytotoxicity in ALL cell lines, and demonstrated that combination therapy with HDACI plus MTX leads to increased induction of apoptosis via modulation of key folate-related genes and increased accumulation of MTX-PG in ALL cell lines.
Materials and methods

Chemicals
Methotrexate and NaBu were obtained from Sigma-Aldrich (St Louis, MO, USA). MTX was dissolved in 1 N NaOH and the pH was adjusted to 7.0. SAHA (vorinostat) 
Cell lines
The human leukemia cell lines CCRF-CEM (T-ALL), SupB15 (Bp-ALL t(9;22)) and REH (Bp-ALL t(12;21)) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The NALM6 (Bp-ALL) cell line was obtained from DSMZ (Braunschweig, Germany). RCH-ACV (Bp-ALL t(1;19)) was provided by Dr Stephen Hunger (The Children's Hospital, Denver, CO, USA). The CCRF-CEM, NALM6, RCH-ACV and REH cell lines were grown in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum at 37 1C and 5% CO 2 . The SupB15 cell line was maintained in IMDM medium (Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum. The HCC1187BL (CRL-2323) cell line derived from peripheral blood lymphocytes immortalized by transformation with Epstein-Barr virus (EBV), grown in RPMI 1640 plus 10% fetal bovine serum, was used for comparison as a model for non-malignant lymphocytes.
Mapping of FPGS gene hypersensitive sites
Nuclei from CCRF-CEM and NALM6 cells were prepared using 0.5% Nonidet-P-40 as described by Elder et al. 23 The nuclei were then digested with 0, 10, 20 and 50 U/ml DNaseI and treated with proteinase-K, and nuclear DNA was extracted twice with phenol and chloroform:isoamyl alcohol prior to ethanol precipitation. Total genomic DNA was restricted with BamHI, size-fractionated on 1% agarose gel and transferred to a BrightStar-Plus nylon membrane (Ambion, Austin, TX, USA). Blots were hybridized with a gel-purified 1374-bp fragment probe labeled with [a- 32 P]dATP using a DECAprime II random priming DNA labeling kit (Ambion). The 1374-bp fragment was generated by PCR amplification using the pCR1374 plasmid as template, which contains the FPGS promoter region. 19 Bands generated by DNaseI nuclease digestion were resolved after exposure to X-ray BioMax MS film (Kodak, Rochester, NY, USA).
Co-immunoprecipitation
Nuclear extracts from NALM6 and CCRF-CEM cells were prepared using a Nuclear Complex Co-IP kit (Active Motif) and equal amounts of 250 mg were pre-cleared with 50 ml of immobilized Gbeads (Pierce Biotechnology, Rockford, IL, USA) and incubated overnight at 4 1C with appropriate antibodies (2.5 mg). The immunoprecipitated samples were subjected to western blot analysis as described previously. 24 The following antibodies were used in this study: CBP (C-1/sc-7300), HDAC1 (C-19/sc-6298), Sp1 (PEP2/sc-59), NFYA (CBF-B; H-209/sc-10779), NFYA (CBF-B; C-1/ sc-7300), NFYB (CBF-A; C-20/sc-7711), NFYB (CBF-A; FL-207/sc-13045), lamin-B (C-20/sc-6216, to normalize the level of protein expression), PCAF (E-8/sc-13124) and normal rabbit and mouse IgG (sc-2025 and sc-2027) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Each experiment was performed at least twice using two independent samples.
DNA affinity precipitation assay
DNA affinity precipitation assay (DAPA) was performed using 1 mg of biotin end-labeled double-stranded oligonucleotides (100 bp) and 250 mg of nuclear extracts from NALM6 or CCRF-CEM cells. The wild-type oligonucleotide included nucleotides À91 to þ 9 of the FPGS gene, which contained six Sp1 (GGGCGG) and two inverted NFY-box (CCAAT)-binding sites. The NFY oligonucleotide mutant contained the two inverted NFY-binding sites mutated to CTTTT, whereas the Sp1 mutated oligonucleotide contained mutations in all of the six Sp1 sites (GGGCGG substituted to GTTTGG). The double mutant NFYSp1 comprised both NFY and Sp1 substitutions. These mutations in the NFY-and Sp1-binding sites were reported to abolish promoter-gene activity. 19, 25 The DNA-protein complexes were precipitated with 60 ml of neutravidin-coated agarose beads (Pierce Biotechnology). The protein complexes were resolved by 12% sodium dodecyl sulfate-PAGE, and CBP, HDAC1, NFYB, PCAF and Sp1 proteins were detected by western blotting.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed using an EZ ChIP Assay Kit (Millipore, Billerica, MA, USA). Briefly, chromatin extracted from NALM6 cells was cross-linked with 1% formaldehyde and DNA sheared to lengths of 200-1500 bp by sonication. Pre-cleared chromatin aliquots were immunoprecipitated overnight at 4 1C with 10 mg of polyclonal antibodies against HDAC1 (sc-6298), NFYB (sc-13045), Sp1 (sc-59), normal rabbit IgG (sc-2025) (Santa Cruz Biotechnology) or acetyl histone H3 (06-599) (Millipore). Complexes were recovered using protein-A-agarose beads, washed and eluted according to the kit instructions. Following cross-linking with 0.2 M NaCl, chromatin DNA was digested with proteinase-K and purified using a QIAquick PCR purification kit (Qiagen, Valencia, CA, USA). The eluted DNA was subjected to PCR amplification to detect the 449-bp fragment of the FPGS promoter region using the primer sets 19679F (5 0 -CC CGGAGCGTACACTCATAAA) and 20109R (5 0 -CGCAGGCCC ACGTGTCGTC). As negative control, a 166-bp fragment of the GAPDH promoter region was PCR-amplified using control primers specific to the GAPDH promoter provided in the EZ-ChIP kit. The PCR products were resolved on 2.5% agarose gel and visualized by ethidium bromide staining. ChIP assays were performed in duplicate using independent chromatin preparations.
Analysis of MTX-PGs
Methotrexate chain PGs were determined using a modification of the procedure described by Pizzorno et al. 26 Briefly, exponentially growing cells were harvested, concentrated to 2.0 Â 10 6 cells/ml and incubated for 4 h in presence of 24 Ci/mmol [3 0 ,5 0 ,7-3 H]-MTX at a concentration of 1 mCi/ml (41.67 nM), and sufficient unlabeled drug was added to achieve a final concentration of 300 nM MTX. The cells were washed twice with cold phosphate-buffered saline (PBS) 1 Â and treated with 1 mM SAHA for 24 h. Following two washes with cold PBS 1 Â , the cells were resuspended in boiling 50 mM sodium phosphate, pH 5.5, for 5 min. Cellular debris were removed by centrifugation at 2000 g for 10 min and the supernatant was filtered through a 0.22 mm cellulose acetate membrane SPIN-X tube (Thomas Scientific, Swedesboro, NJ, USA). The supernatant was stored at À80 1C until analysis by high-performance liquid chromatography. An aliquot of the cell extract containing approximately 5000-10 000 c.p.m. was 'spiked' with unlabeled known PG standards (MTX-Glu1-7) (Schircks Laboratories, Switzerland) and injected onto a reverse C18 column (Grace Division Discovery Sciences, Deerfield, IL, USA), with gradual elution of 50 mM sodium phosphate (pH 5.4) and 40% acetonitrile using a high-performance liquid chromatography system (Beckman Coulter System Gold HPLC, Fullerton, CA, USA). The c.p.m. value of each 0.5 ml elution tubes was determined using a LS6500 Scintillation Counting System (Beckman Coulter, Fullerton, CA, USA).
RNA isolation and TaqMan real-time qRT-PCR
Total RNA was isolated from cells using an RNeasy kit (Qiagen). First-strand cDNA synthesis was performed using AMV reverse transcriptase (Promega, Madison, WI, USA). The level of expression of ATP-binding cassette subfamily-C (ABCC1), DHFR, FPGS, g-glutamyl hydrolase (GGH), solute carrier family 19/folate transporter (SLC19A1, formerly RFC) and thymidylate synthetase (TS) mRNA was quantified using primers and TaqMan probes (IDT) as described. [27] [28] [29] For all genes, we used 6-carboxyfluorescein (FAM) as reporter dye. The relative level of mRNA gene expression was normalized using a hexachlorofluoresceinlabeled b-actin probe. Each of the probes was quenched using Black Hole Quencher-1 at its 3 0 -end. All TaqMan qRT-PCR assays were performed using an iQ Supermix on the iCycler iQ5 system (Bio-Rad, Hercules, CA, USA). Each experiment was performed at least twice with four independent samples.
Sodium butyrate, SAHA and MTX cytotoxicity assays
For the combination of NaBu and MTX, logarithmically growing cells were sequentially exposed to NaBu EC 50 concentrations (2 mM for NALM6, REH, SUPB15; 5 mM for CCRF-CEM) for 24 h and to MTX EC 50 concentrations (400 nM for NALM6 and REH; 700 nM for SUPB15; 1 mM for CCRF-CEM) for 4 h. Following drug treatment, viable cell concentration was assessed using the Vi-CELL XR (Beckman Coulter) and cell cultures washed twice with cold PBS 1 Â , resuspended in drug-free medium and diluted to the pre-washed cell concentration. When SAHA and MTX cytotoxicity was assayed, exponential cultures of NALM6, REH, SUPB15 and CCRF-CEM cells were exposed to 300 nM (NALM6, REH, SUPB15) or 800 nM (CCRF-CEM) MTX for 4 h, washed twice with cold PBS 1 Â and treated with SAHA (1 mM for CCRF-CEM, NALM6, REH; 2 mM for SUPB15) for 24 h. Following each treatment, viable cell counts were determined and cell cultures were washed twice with cold PBS 1 Â , resuspended in drug-free medium and diluted to the pre-washed cell concentration. Viable cell counts were assessed after 48 and 72 h of drug exposures. To evaluate drug interactions in combination cancer therapy, we used combination index (CI) analyses, which provides qualitative information on the nature of drug interaction and a quantitative measure of the extent of drug interaction using the formula CI ¼ (CA,x/ICx,A) þ (CB,x/ICx,B). 30 The CI for each drug combination was calculated using the CI equation described by Chou. 31 A CI of o1.0 represents synergism.
Assessment of apoptosis with Annexin-V staining
Apoptosis was assessed by Annexin-V-fluorescein isothiocyanate and propidium iodine staining (BD Pharmingen, San Diego, CA, USA) according to the manufacturer's instructions. Percentage of apoptotic cells was determined by flow cytometry analysis using the BD LSR II system (BD Biosciences, San Jose, CA, USA).
Flow cytometry assessment of cell cycle
Cells were cultured in six-well plates and treated with SAHA prior to assessment of cellular DNA content by flow cytometry as previously described. 32 Briefly, treated cells were washed twice with PBS and 2.0 Â 10 6 cells were resuspended in 70% ethanol and fixed overnight at 4 1C. Subsequently, cells were washed twice with PBS and suspended in 0.5 ml of propidium iodine/RNase solution (BD Pharmingen) and cell-cycle progression was determined by flow cytometry (BD Biosciences FACSCalibur flow cytometer).
Results
Identification of a DNaseI-hypersensitive site upstream of exon-1 in B-and T-ALL
To identify putative regulatory regions in the vicinity of the FPGS gene we performed DNaseI hypersensitivity assays in CCRF-CEM (T-ALL) and NALM6 (Bp-ALL) cells. As shown in Figure 1 , untreated nuclei extracted from both cell lines generated a 10-kb BamHI fragment with the 1374-bp fragment as probe (see Materials and methods). When NALM6 nuclei were treated with DNaseI, a 9-kb band was detected at low concentration (10 U/ml). In contrast, CCRF-CEM cells required significantly higher DNaseI concentration (50 U/ml) to release the 9-kb BamHI fragment. The 9-kb DNaseI-hypersensitive site mapped closely upstream from exon-1 in a region containing eight concatameric Sp1 (GGGCGG) and two inverted NFY (ATTGG) putative binding sites, previously shown to play a role in the regulation of the FPGS promoter. The more opened chromatin structure identified in the FPGS promoter region of NALM6 as compared with CCRF-CEM cells suggests that chromatin remodeling plays a role in the lineage differences in FPGS mRNA expression previously reported in ALL cells (that is, higher constitutive expression of FPGS in Bp-ALL as compared with T-ALL).
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HDAC1 interacts with NFY and Sp1 in vivo in Bp-ALL and T-ALL
We and others have previously demonstrated that NFY and Sp1 transcription factors are required for optimal FPGS gene expression in ALL cell lines. 19, 33 It has been shown that Sp1 associates with HDAC1 to regulate gene expression 21, 34 and therefore, HDAC1 inhibitors can lead to enhanced activity of promoters containing Sp1-binding sites. 21, 22 On this basis, we hypothesized that an HDAC-associated protein complex could regulate FPGS gene expression through chromatin remodeling.
To test this hypothesis and to uncover any potential interactions between HDAC1, CBP, NFY, PCAF and Sp1 proteins within this complex in NALM6 and CCRF-CEM cells, co-immunoprecipitation and immunoblotting experiments were performed. As shown in Figure 2a 
HDAC1, NFY-B and Sp1 interact with the FPGS promoter region in ALL cell lines
To investigate HDAC1, NFY and Sp1 interactions and binding specificity to the FPGS promoter region, we performed DAPA and immunoblot analysis using biotin-labeled oligonucleotides spanning nucleotides À91 to þ 9, which include six Sp1 (GGGCGG) and two inverted CCAAT box (NFY box). The oligonucleotides were designed to contain either the wild-type sequence or mutated NFY-and Sp1-binding sites. Nuclear extracts from NALM6 and CCRF-CEM were used for these assays. As shown in Figure 3 , NFYB strongly binds to the wildtype oligonucleotide (À91/ þ 9 region of the FPGS promoter; lanes 2 and 3) as detected with an NFYB-specific antibody, and to the Sp1 mutants (lanes 6 and 7), but significantly less to the NFY mutants (lanes 4 and 5) or the double NFY-Sp1 mutants (lane 8). Similarly, Sp1 strongly binds to the wild-type À91/ þ 9 region of the FPGS promoter ( Figure 3 , lanes 2 and 3), to the NFY mutants (lanes 4 and 5), but to a lesser extent to the SP1 mutants (lanes 6 and 7), and significantly less to the double NFY-Sp1 mutants (lane 8). Finally, we found that HDAC1 binds to the wild-type oligonucleotide (lanes 2 and 3), to both NFY and Sp1 mutants (lanes 4-7), but significantly less to the double NFY-Sp1 mutants (lane 8), which was similar to the negative control (lane 1). Under our experimental conditions, additional DAPA experiments did not detect signal indicative of interactions between NFY, Sp1 and HAT proteins (p300, CREB, PCAF) and the FPGS promoter. Taken together, these data show that both NFY and Sp1 interact to recruit HDAC1 to the FPGS promoter region. Alternatively, HDAC1 binding (lanes 6 and 7) may reflect the interaction with the Sp1 fraction that managed to bind to the fragment. To demonstrate that these interactions occur on native chromatin structure at the FPGS promoter locus, we performed ChIP assays. Chromatin from NALM6 cells was immunoprecipitated with HDAC1, NFY-B and Sp1 antibodies, and DNA was subjected to PCR amplification using primer sets designed to amplify a 449-bp fragment of the FPGS promoter region as described under Materials and methods. As shown in Figure 4 , the 449-bp PCR product was detected in NALM6 cells chromatin immunoprecipitated with HDAC1, NFY-B and Sp1 antibodies, but not with normal rabbit IgG or negative control without antibody, indicating that NFY, Sp1 and HDAC1 are associated to the active chromatin structure of the FPGS promoter region. Additional PCR amplifications using control primers specific to the GAPDH promoter DNA region were performed to demonstrate the specificity of NFY, HDAC1 and Sp1 interactions to the FPGS promoter region. In our NALM6 ChIP assays, the GAPDH promoter DNA was not pulled down by NFY-B and HDAC1 antibodies, indicating that NFY, HDAC1 and Sp1 interactions were specific to the FPGS promoter region (data not shown). These ChIP data correlate with our DAPA data, and provide strong evidence of the regulatory role of NFY, Sp1 and HDAC1 binding to the promoter region of the FPGS gene.
Treatment with HDAC inhibitors induces FPGS mRNA expression
To test the effect of chromatin remodeling on the regulation of the FPGS promoter, we investigated the effect of the HDACIs NaBu and SAHA on the expression of FPGS. In related experiments we also tested their effect on the expression of other folate-related genes known to alter the metabolism of antifolates in ALL cells. The level of FPGS, ABCC1, DHFR, GGH, SLC19A1 and TS mRNA gene expression were determined by quantitative TaqMan real-time qRT-PCR using NALM6 (Bp-ALL), REH (Bp-ALL, t(12,21)/ TEL-AML1), SupB15 (Bp-ALL, t(9,22)/BCR-ABL) and CCRF-CEM (T-ALL) cells treated with NaBu (2-5 mM) or SAHA (1-2.5 mM) for 24 h. In all cell lines examined, treatment with NaBu or SAHA induced a 1.5-to 6-fold increase in the level of FPGS and ABCC1 mRNA expression, whereas the level of DHFR, SLC19A1 and TS mRNA expression decreased by a similar proportion ( Figure 5 and Table 1 ). The expression level of GGH mRNA was found unaltered in Bp-ALL and T-ALL cell lines treated with NaBu or SAHA (Table 1) . When EBV-immortalized non-malignant lymphocytes (HCC1187BL cells) were treated with SAHA (0.5, 1, 2 and 4 mM) for 24 h and gene expression was analyzed using quantitative TaqMan real-time qRT-PCR, no changes in Figure 4 Chromatin immunoprecipitation of HDAC1, NFYB and Sp1 proteins in NALM6 cells. The chromatin extracted from NALM6 cells was immunoprecipitated with HDAC1, NFYB and Sp1 antibodies and purified DNA was subjected to PCR using primer sets designed to amplify a 449-bp fragment of the FPGS promoter region as described under Materials and methods. All pre-cleared chromatin supernatant samples yielded a similar amount of the 449-bp PCR-amplified DNA fragment from the FPGS promoter region. The ethidium bromidestained agarose gel shows a representative sample of input DNA (5%) from pre-cleared chromatin supernatants; the PCR products from chromatin immunoprecipitated using specific antibodies, normal rabbit IgG, no antibody and PCR-negative control are shown. The two PCR lanes for NFYB and Sp1 represent ChIP assays performed in duplicate. ChIP, chromatin immunoprecipitation; FPGS, folylpoly-gglutamate synthetase; HDAC, histone deacetylase. Figure 5 The effect of NaBu and SAHA on FPGS mRNA gene expression in ALL cell lines. NALM6, SUPB15, REH and CCRF-CEM cells were treated for 24 h with NaBu (2 mM for Bp-ALL and 5 mM for T-ALL) or SAHA (1 mM for NALM6, REH, CEM; 2.5 mM for SUPB15). Total RNA was extracted and FPGS mRNA expression determined by qRT-PCR (see Materials and methods). FPGS mRNA expression was normalized to b-actin and data are expressed as fold change in expression detected in treated versus untreated cells. ALL, acute lymphoblastic leukemia; Bp-ALL, B-precursor-ALL; ChIP, chromatin immunoprecipitation; FPGS, folylpoly-g-glutamate synthetase; HDAC, histone deacetylase; NaBu, sodium butyrate; qRT-PCR, quantitative reverse transcription-PCR; SAHA, suberoylanilide hydroxamic acid; T-ALL, T-lineage ALL. FPGS expression were observed indicating the effects on gene expression were limited to the leukemia cell models analyzed (data not shown). Therefore, treatment of Bp-ALL and T-ALL cell lines with HDACI upregulates FPGS mRNA and alters the expression of other folate-related genes in a manner capable of altering MTX metabolism and increasing the accumulation of antifolate polyglutamtates. To determine whether HDACI-induced FPGS mRNA expression resulted from increased histone acetylation, we performed ChIP assays using an anti-acetyl histone H3 antibody. Treatment of NALM6 and REH cells with 1 mM SAHA for 24 h was found to increase the level of histone H3 acetylation at the FPGS promoter region (data not shown), indicating that induced FPGS transcriptional activation by SAHA is associated with increased acetylation of histones.
To determine the effect of HDACI on cell-cycle arrest and its potential consequences on gene expression, we examined the cell-cycle progression of ALL cell lines treated with SAHA (1-2 mM) for 24 h using flow cytometry. We found that SAHA induced a G 0 /G 1 cell-cycle arrest in NALM6, REH and CCRF-CEM cells, whereas SUPB15 cells were arrested in G 2 /M (data not shown).
SAHA increases the intracellular accumulation of long-chain MTX-PG in ALL cell lines
To evaluate the pharmacological effect resulting from SAHAinduced increased FPGS mRNA expression, we determined the intracellular accumulation of MTX-PGs in ALL cell lines following treatment with SAHA. Logarithmically growing NALM6 and REH cells were exposed to 300 nM [ 3 H]-MTX for 4 h, washed twice with PBS and treated with 1 mM SAHA for 24 h. Intracellular drug metabolites were determined by highperformance liquid chromatography as described under Materials and methods. As shown in Table 2 , the levels of long-chain PGs MTX-GLU 4À7 were significantly higher in cells treated with SAHA when compared with those in controls (NALM6, 7.8 versus 6 pmol/10 7 cells; REH, 3.6 versus 2.7 pmol/10 7 cells). Similarly, total MTX-PGs (nX2) were higher in cells treated with SAHA as compared with untreated cells.
MTX and SAHA combination therapy induces synergistic cytotoxicity and apoptosis in B-ALL cell lines
The mRNA expression data led us to hypothesize that during MTX treatment, induction of FPGS expression by HDACI leads to increased cytotoxicity via enhanced polyglutamation and intracellular accumulation of MTX-PG. In addition, concomitant decrease in the expression of the enzymes DHFR and TS inhibited by MTX-PGs, should enhance the synergism of the combination HDACI plus MTX in ALL cells. To test this hypothesis, CCRF-CEM (T-ALL), NALM6 (Bp-ALL), REH (Bp-ALL expressing TEL/AML1) and SupB15 (Bp-ALL expressing Bcr/Abl) cells were treated sequentially with MTX (4 h) and SAHA (24 h) at EC 50 concentrations, and apoptotic cell death was assessed by Annexin-V binding to phosphatidylserine exposed on the surface of apoptotic cells after 48 h. These cell lines were chosen as representative of ALL phenotypes with distinct MTX sensitivities and metabolic profiles, including the TEL/AML1-positive REH cell line known to accumulate low levels of MTX-PGs 35, 36 and the highly chemotherapy-resistant, Bcr/Abl-positive SUPB15 cells.
35 Table 1 Fold change in the level of folate-related genes mRNA expression detected in treated (NaBu and SAHA) versus untreated ALL cell lines As shown in Figure 6 , treatment with MTX þ SAHA significantly increased apoptosis in NALM6 (Po0.01) and REH cells (Po0.01) as compared with exposure to each drug alone. To evaluate the synergism, cell viability was determined in NALM6, REH, SUPB15 and CCRF-CEM cells after treatment with MTX (4 h) þ SAHA (24 h) as detailed under Materials and methods. As shown in Figure 7 , treatment with MTX þ SAHA significantly decreased cell viability in NALM6 (Po0.01), REH (Po0.01), SUPB15 (Po0.05) and CCRF-CEM cells (Po0.001) as compared with exposure to each drug alone. The calculated CIs, using the equation described by Chou. 31 (see Materials and methods), were 0.77 for NALM6, 0.67 for REH, 0.63 for SUPB15 and 0.84 for CCRF-CEM cells, indicating strong synergy for all the cell lines. Sequential treatment with NaBu þ MTX similarly increased the level of cell death in NALM6 (18%), REH (12%), SupB15 (15%) and CCRF-CCEM (21%) cells after 24 h of exposure when compared with exposure to each drug alone (data not shown). When other treatment schedules were studied, such as simultaneous exposure to both MTX and SAHA, or sequential treatment with SAHA followed by MTX, no synergism was observed, indicating the schedule dependency for efficacy of this combination. It is likely that the observed cell-cycle arrest following SAHA and/or changes in the expression of the transport and efflux genes (upregulation of ABCC1 and downregulation of SLC19A1) are responsible for the lack of synergism observed with these alternative schedules.
Discussion
Acute lymphoblastic leukemia is the most common childhood hematological malignancy. Despite significant progress and success in the treatment of ALL, a significant number of children continue to relapse and for them, outcome is dismal. 1 Likewise, outcome for others who are diagnosed with chemotherapyresistant phenotypes, such as Bcr/Abl-positive; MLL-rearranged ALL, induction failures and severe hypodiploid, remains poor. Therefore, effective molecular targeted agents need to be identified and integrated into novel treatment schemas incorporating a backbone of proven cytotoxic chemotherapy combinations. In this context, data from the present study indicate that co-administration of a clinically relevant HDACI (SAHA) plus the highly effective antileukemic drug MTX synergizes to induce apoptotic death in ALL cells.
The ongoing evolution of cancer therapy includes the use of molecular targeted agents chosen on the basis of a rational understanding of the biological mechanisms that operate in individual cancers. Among these, drug metabolism by cancer cells is critical in determining response to therapy. Regulation of gene expression, including genes that determine drug metabolism, is complex, but epigenetic mechanisms have emerged as fundamental in orchestrating gene expression within the human genome. Among these, histone acetylation and deacetylation allow changes in chromatin structure around the gene promoter regions that permit binding of specific transcription factors that enhance or repress transcription. HDACIs have been shown to be cytotoxic alone or when combined with other agents in a variety of transformed cells, including various hematological malignancies. 37 Using a NOD/SCID mouse model, Einsiedel et al. 38 have shown that HDACI such as SAHA have in vivo therapeutic potential in B-cell precursors. Recently, several phase-I studies using SAHA (vorinostat) in advanced leukemias and myelodysplastic syndromes have demonstrated that SAHA is safe when administered orally and exhibited significant antileukemic activity. [39] [40] [41] Consequently, SAHA is currently being evaluated in several phase-II studies of patients with hematologic and solid-tumor malignancies. 42 SAHA also has shown synergism in hematological malignancies when combined with a wide variety of agents such as the Src kinase-family inhibitor dasatinib; 43 the heat-shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin; 44 the cyclin-dependent kinase inhibitor flavopiridol; 45 the nuclear factor-kB inhibitor Bay 11-7082; 46 the Bcr/Abl TK inhibitors imatinib and MK-0457; 47, 48 the MEK1/2 inhibitor PD184352; 49 the proteasome inhibitor bortezomib 50, 51 and DNA topoisomerase-II inhibitors, 52 among others. In the present study, we found that treatment of ALL cell lines with HDACI (SAHA and NaBu) altered gene expression within the folate pathway in a manner that favored intracellular accumulation of MTX-PGs and enhanced the inhibition of its enzymatic targets. Both SAHA and NaBu induced 1.5-to 6-fold increase in FPGS expression, which encodes for the enzyme responsible for converting the parent drug to its active metabolite (MTX-PG), and decreased DHFR and TS expression, the two main targets of MTX-PGs, by two-fold. Consistent with our data, HDACIs (trichostatin-A and SAHA) were recently reported to downregulate TS and overcome 5-fluorouracil resistance in models of gastrointestinal malignancy. 53, 54 Alternatively, the observed downregulation of TS and DHFR in ALL cell lines treated with SAHA or NaBu could result from the observed cell-cycle arrest induced by these agents rather than a direct effect on gene expression. Since no significant difference was found in the level of GGH mRNA expression and both FPGS and GGH activities determine the intracellular metabolism to MTX-PGs, we conclude that once MTX is inside the cells, accumulation of MTX-PGs is exclusively dependent on FPGS expression in cells treated with HDACIs. When considering other observed changes in gene expression, such as decrease in SLC19A1 and increase in ABCC1 expression in isolation, one would expect decreased MTX uptake and MTX-PG accumulation. Nevertheless, under these experimental conditions our data suggest an 'overriding' effect of FPGS expression on MTX-PG accumulation. In childhood ALL, the cell lineage of origin and presence of non-random chromosomal aberrations determine the molecular phenotype responsible for treatment outcome. We previously reported that the constitutive expression of the FPGS gene in ALL lymphoblasts is controlled in a lineagespecific manner, with Bp-ALL cells expressing significantly higher FPGS mRNA and activity as compared with T-ALL lymphoblasts. 10 We now provide data suggesting that the mechanism responsible for this lineage specificity is epigenetic and that chromatin structure around the FPGS gene promoter influences the lineage-specific constitutive expression of FPGS in Bp-ALL and T-ALL. The FPGS promoter lacks a TATA-box and contains eight putative Sp1 (GGGCGG) and two inverted NFY (CCAAT) transcription binding sites, which positively regulate its expression. 18, 19, 33 Using co-immunoprecipitation, DAPA and ChIP assays, we uncovered interactions between NFY, Sp1 and HDAC1 in ALL cell lines and demonstrated that both Sp1 and NFY transcription factors bind strongly to the native chromatin structure of the FPGS promoter region. More importantly, our DAPA and ChIP assays demonstrate that Sp1 and NFY interact to cooperatively recruit HDAC1 to the FPGS promoter region, and assembly of this complex would lead to decrease FPGS mRNA expression. Consequently, as observed, treatment with HDACIs would alter the FPGS promoter acetylation status, modify its chromatin structure and lead to increased FPGS gene transcription. Similar interactions between NFY, Sp1 and HDAC1 have been reported in other TATA-less promoters such as the transforming growth factor-b type-II receptor (TbRII) 55 and the HDAC1 promoter. 56 In the TbRII gene, HDAC activity selectively blocked the ability of Sp1-and NFY-binding sites to activate the TbRII promoter transcription and allow the PCAF protein to associate to the NFY complex to bind to the CCAAT-box in the TbRII promoter. 55, 57 Histone deacetylase-1 inhibitors have been shown to enhance the transcription activity of promoters in a variety of cellular and viral genes containing Sp1-binding sites. [58] [59] [60] [61] [62] Sp1 belongs to the Sp family of transcription factors (Sp1-Sp4) that bind to the same consensus sequences (GGGCGG). 63 As other factors can also interact with Sp1, competition between transcription factors and HDACs may represent a general way to regulate gene expression via reversible modifications of chromatin structure. 57 Alternatively, repression of genes mediated by HDAC1 binding to Sp1 sites may represent a mechanism of regulation to control gene expression during the cell cycle. For instance, it has been shown that HDAC1 interacted with Sp1 to repress the dihydrofolate reductase (dhfr ) gene in quiescent cells (G 0 ). 58 In dhfr, the Sp1 sites are also responsible for basal levels of expression throughout the cell cycle and induction at the G 1 /S boundary after growth stimulation. 64, 65 Data from our laboratory indicate that the FPGS gene is upregulated in the G 1 phase prior to progress into S-phase in anticipation of increased folate and nucleoside requirements for DNA replication (Leclerc and Barredo, unpublished data) . This suggests the possibility that HDAC1 could also regulate FPGS expression throughout the cell cycle. Ongoing experiments will address this mechanism. Alternatively, HDAC1 could also participate in the regulation of FPGS expression by modulating the levels of NFY and Sp1 acetylation. Additional experiments investigating the level of NFY and Sp1 acetylation should clarify this role for HDAC1.
In this report we have demonstrated that HDAC1 is recruited by NFY-B and Sp1 proteins to the FPGS promoter in a multiprotein complex that includes CBP and likely others, to regulate FPGS mRNA expression epigenetically through chromatin remodeling. Although our data did not show a role for HAT proteins in this mechanism, we cannot rule out the possibility that HAT proteins could activate FPGS transcription by binding to NFY and/or Sp1. Further, transcription factors other than NFY and Sp1 could also be involved in the binding and recruitment of HAT to the FPGS promoter. For instance, interactions between NFY and HAT proteins such as the coactivator p300 [66] [67] [68] [69] [70] [71] have been described previously. This dual mechanism of regulation involving both HATs and HDACs has recently been shown for the TbRII promoter in which transforming growth factor-b expression was found to be induced both by trichostatin-A, a HDACI, and by acetylation of Sp1 after recruitment of PCAF/ p300 to an Sp1/NFY complex. 55 Similarly, NFY and Sp1/Sp3 have been found to regulate the transcriptional activation and repression of HDAC1 synergistically by recruiting either HATs or HDACs, respectively, to the HDAC1 promoter. 56 Cellular accumulation of MTX-PGs is recognized as an important determinant of MTX cytotoxicity in ALL lymphoblasts. 12, 13, 72 Our laboratory and others have previously demonstrated that Bp-ALL cells express 2-to 3-fold higher levels of FPGS mRNA, protein, enzyme activity, and accumulate higher intracellular concentrations of MTX-PGs as compared with T-ALL. 10, 14 The ability of cells to accumulate higher intracellular concentrations of MTX-PGs correlates with their in vitro and in vivo sensitivity to MTX.
14 This is consistent with the higher IC 50 for MTX in CCRF-CEM (T-ALL) as compared with in NALM6 and other Bp-ALL cells in our study and other reports. 14 The data presented here, demonstrate that upregulation of FPGS mRNA expression by SAHA results in a net pharmacological increase of 30% in intracellular of long-chain MTX-PGs accumulation in ALL cell lines as compared with that in untreated control. Further, long-chain MTX-PGs inhibit not only DHFR but also other important folate pathway enzymes such as TS and aminoimidazolecarboxamide ribonucleotide formyltransferase. In mammalian cells, DHFR converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for de novo synthesis of purines, thymidylic acid, and certain amino acids, whereas TS is required to generate thymidine monophosphate (dTMP), which is subsequently phosphorylated to thymidine triphosphate for use in DNA synthesis and repair. Therefore, concomitant inhibition of DHFR and TS leads to enhanced impairment of DNA synthesis and subsequent cell-cycle arrest, enhancing the cytotoxic effect of MTX-PG. In addition, the observed increase in SLC19A1 (reduced folate carrier) and decrease in ABCC1 expression, responsible for influx and efflux of MTX in mammalian cells, respectively, appear not to alter the observed pharmacological profile when MTX was administered followed by SAHA as described. Conversely, the lack of synergism observed when both drugs were administered concomitantly or when SAHA was administered first followed by MTX, may be partially explained by changes in MTX transport resulting from altered expression of SLC19A1 and/or ABCC1. An alternative explanation for the schedule dependency of this combination would be that the cell-cycle arrest known to be induced by SAHA abrogates the effects of a growth-dependent agent such as MTX when administered concomitantly with or before the antifolate. When used as single agents, both MTX and SAHA can induce cell death, growth arrest and apoptosis. 22, 73, 74 Our results demonstrate that MTX plus SAHA synergistically increased apoptotic cell death and decreased viability in all Bp-ALL and T-ALL cell models tested. Of note, the CI for the highly chemotherapyresistant, Bcr/Abl-positive SUPB15 was 0.63, indicating strong synergy. In addition, REH cells (TEL/AML1-positive Bp-ALL) known to accumulate significantly lower levels of MTX-PG in vitro and in vivo 35, 36 accumulated higher levels of MTX-PG when treated with SAHA plus MTX as compared with control treated with MTX only, also resulted in synergism (CI o0.63). Taken together, the pharmacological advantage of the combination treatment of MTX and SAHA in ALL lymphoblasts stems from their synergistic effect on (i) the induction of the FPGS mRNA level leading to increased synthesis of long-chain MTXPGs (nX3) and (ii) decreased expression of the two key target enzymes DHFR and TS. The pharmacokinetics of SAHA have been studied after single daily dosing of 400 mg repeated for 22 days and in this schedule the maximum concentration (C max ) was found to be 1.12 mmol/l, with a half-life approaching 2 h and a peak concentration approaching 1 mM. 75 Additional studies have investigated twice daily dosing at 400 mg and once daily at 600 mg for three consecutive weeks. 40 The pharmacodynamic profile of SAHA demonstrates that changes in histone acetylation persist beyond the time in which the drug's peak plasma concentrations have decreased, suggesting that maintaining high peak plasma concentration for prolonged periods of time may not be required to obtain the desired biological effects. 41 The latter needs to be appropriately tested in a phase-I/II clinical trial. Therefore, on the basis of the known pharmacokinetic/pharmacodynamic profile of SAHA and on our data, a phase-I/II study investigating the pharmacokinetics and tolerability of SAHA administered every 8 or 12 h over 24 h following treatment with MTX would be warranted in patients with ALL.
In conclusion, we have provided evidence that HDAC1 is recruited by NFY-B and Sp1 proteins to the FPGS promoter in a multi-protein complex, which may include CBP and likely others, to epigenetically regulate FPGS mRNA expression through histone modifications and chromatin remodeling. The net pharmacological effect of SAHA-induced increase in FPGS expression in ALL cell lines is higher intracellular accumulation of long-chain MTX-PGs, the active metabolites of MTX. Concomitantly advantageous is the demonstrated decrease in expression of two key MTX-PG target enzymes, DHFR and TS. Therefore, when combined, MTX and HDAC inhibitors (SAHA or NaBu) synergize to induce apoptosis in Bp-ALL and T-ALL cells. The strong synergism exhibited by this combination warrants testing in phase-I/II clinical trials for ALL patients, in particular those who exhibit phenotypes with de novo or acquired resistance to MTX.
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